Plain English Summary
PYY 3-36 is a peptide hormone derived from peptide YY, which plays a significant role in regulating appetite and energy metabolism. It has potential therapeutic applications in obesity and opioid use disorder, impacting food intake, glucose levels, and stress responses in animal models.
What People Use It For
Side Effects & Risks
Common Side Effects
References
- 1https://pubmed.ncbi.nlm.nih.gov/28003328/
- 2https://pubmed.ncbi.nlm.nih.gov/37572954/
- 3https://pubmed.ncbi.nlm.nih.gov/37001706/
- 4https://pubmed.ncbi.nlm.nih.gov/40629530/
- 5https://pubmed.ncbi.nlm.nih.gov/22975597/
- 6https://pubmed.ncbi.nlm.nih.gov/38542814/
- 7https://pubmed.ncbi.nlm.nih.gov/26006332/
- 8https://pubmed.ncbi.nlm.nih.gov/34272643/
Researchers also explore
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.
GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is an endogenous incretin hormone released from the gut after nutrient intake. It plays a critical role in glucose metabolism by stimulating insulin secretion in a glucose-dependent manner. While historically studied for its insulinotropic effects, modern research focuses on its systemic roles in adipose tissue, bone remodeling, and the central nervous system, particularly when combined with GLP-1 for metabolic therapies.
Glucose-dependent insulinotropic polypeptide (GIP)
GIP is an incretin hormone secreted by the intestine that plays a key role in glucose metabolism and energy homeostasis. While traditionally recognized for its role in stimulating insulin secretion in response to nutrient intake, recent research highlights its involvement in lipid metabolism, bone health, and neurological function. It is currently a focal point of therapeutic development in combination with GLP-1 agonists for treating obesity and metabolic disease.
Researcher Sentiment
No votes yet — be the first
Educational Content Only
This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.